The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Fish Oil Eases Hep C Therapy-Related Anemia

Back to News Homepage

Next

Combining Well Care and Sick Care for Hepatitis C

Danoprevir Demonstrated an 85% Sustained Virologic Response Rate

December 18, 2013

Print this page

Learn about the positive results from phase 2 trials of adding danoprevir to the current treatment regimen (peginterferon alfa-2a/ribavirin) for Hepatitis C.

New hepatitis C drug shows potential in phase 2 trials

The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association. The current standard of care for hepatitis C patients includes a combination of peginterferon and ribavirin.

“Despite recent advances, the current hepatitis C treatment regimen is burdensome on the patient and prone to adverse events,” said Patrick Marcellin, lead study author from the Service d’Hépatologie and Inserm CRB3, Hôpital Beaujon, APHP University of Paris. “The promising results from this study offer hope that danoprevir can improve the quality of life for patients suffering from this disease.”

Continue reading this entire article:
http://www.thealmagest.com/new-hepatitis-c-drug-shows-potential-phase-2-trials/7267

1 Comment
Share
Share

Previous

Fish Oil Eases Hep C Therapy-Related Anemia

Back to News Homepage

Next

Combining Well Care and Sick Care for Hepatitis C

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.

  • Gus

    At least 50% of victims have already tried the old drugs and the drugs didn’t work or caused such horrific side effects that they discontinued treatment. So adding more new drugs to the old drugs doesn’t make any sense for at least 50% of hep victims.